Seraxis gathers $40m Series C
Seraxis, a developer of cell replacement therapy for insulin-dependent diabetes, has secured $40 million in Series C financing.
10 February 2021•1 min read
Seraxis, a developer of cell replacement therapy for insulin-dependent diabetes, has secured $40 million in Series C financing.
Inovia hits $200m in first close for sixth early-stage fund
19 October 2026 · 4 mins read
San Joaquin County to slow venture commitments
15 October 2026 · 2 mins read
DOWNLOAD: Fundraising holds steady in Q3
14 October 2026 · 2 mins read
Why Endeavor Catalyst is betting big on Southeast Asia
8 October 2026 · 4 mins read
Dig's new fund bets on infrastructure built around foundation models
6 October 2026 · 4 mins read
Meet venture capital’s 2026 Women of Influence
5 October 2026 · 4 mins read
Eyeing opportunities and how the Women of Influence see trends developing
5 October 2026 · 3 mins read
